Clinical Trial Update: Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fosaprepitant with ondansetron versus ondansetron alone for preventing chemotherapy-induced nausea and vomiting in pediatric patients; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Ondansetron (ondansetron)
• fosaprepitant (MK-0517) + ondansetron

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: TERMINATED | Results posted: 2018-03-08